IGF-1 LR3

What is IGF-1 LR3?

IGF-1 LR3 (also known as Long R3-IGF-1 or Long Arg3 Insulin-like Growth Factor-1) is a synthetic, recombinant 83-amino acid analog of human insulin-like growth factor-1 (IGF-1). It features two distinct modifications designed to maximize metabolic lifespan: the replacement of glutamic acid with arginine at position 3, and a 13-amino acid extension at the N-terminus. Originally developed to enhance cellular proliferation in industrial biotechnology, researchers investigate this compound for its prolonged biological half-life, cell survival activation, and systemic growth mediation.

For laboratory and in vitro evaluation, researchers often choose to buy IGF-1 LR3 in high-purity lyophilized form. In addition, reconstitution solution can be used to provided stability to preserve complex research peptides and compounds and minimize surface adsorption during experimental protocols.

Chemical and Molecular Data

What are the Mechanisms of Action?

The biochemical pathways and cellular targets of IGF-1 LR3 include:

• IGF-1 Receptor Agonism: Research demonstrates that IGF-1 LR3 binds directly to the human type 1 insulin-like growth factor receptor (IGF-1R), inducing conformational changes that initiate internal tyrosine kinase transphosphorylation.
• Sequestration Evasion (IGFBP Avoidance): Due to its engineered structural modifications, the peptide exhibits dramatically reduced binding affinity for insulin-like growth factor-binding proteins (IGFBPs). This prevents binding proteins from capturing and disabling the compound, maximizing local and systemic free ligand concentrations.
• Intracellular Cascade Activation: Unbound interaction with IGF-1R triggers critical downstream cascades, notably the PI3K/Akt pathway for cellular survival and protein synthesis mediation, alongside the Ras/MAPK/ERK pathway for coordinated tissue proliferation and differentiation.

What are the Clinical & Preclinical Trials on IGF-1 LR3?

When evaluating research efficacy and published experimental literature for IGF-1 LR3:

• Anabolic Performance and Bioavailability: Preclinical investigations documented in classic endocrinology models evaluated the clearance dynamics of infused IGF-1 analogs. They observed that the LR3 modification preserves absolute anabolic potency in vivo by avoiding binding protein sequestration, demonstrating a three-fold increase in structural stability compared to native IGF-1.
• Tissue Remodeling Trials: Complex animal models tracked via PMC Research streams demonstrated that continuous systemic administration of the stable Long R3 IGF-1 analog effectively modulates vascular smooth muscle cell phenotypes and structural core stabilization metrics during cellular stress assays.
• Safety & Potency Profiles: Across isolated cell culture assays, IGF-1 LR3 established high reproducibility, clear dose-response patterns, and minimal cross-reactivity with traditional insulin receptors at default research concentrations.

How does IGF-1 LR3 compare to other compounds?

To evaluate receptor affinity, clearance profiles, and target tissue specificity, researchers compare IGF-1 LR3 against truncated variants and mechanical splice variations: